作者: Santiago Guerrero , Andrés López-Cortés , Alberto Indacochea , Jennyfer M. García-Cárdenas , Ana Karina Zambrano
DOI: 10.1038/S41598-018-32264-X
关键词:
摘要: Over the past decades, consistent studies have shown that race/ethnicity a great impact on cancer incidence, survival, drug response, molecular pathways and epigenetics. Despite influence of in outcomes its health care quality, comprehensive understanding racial/ethnic inclusion oncological research has never been addressed. We therefore explored composition samples/individuals included fundamental (patient-derived models, biobanks genomics) applied (clinical trials). Regarding patient-derived models (n = 794), 48.3% no records their donor’s race/ethnicity, rest were isolated from White (37.5%), Asian (10%), African American (3.8%) Hispanic (0.4%) donors. Biobanks (n = 8,293) hold specimens unknown (24.56%), (59.03%), (11.05%), (4.12%) other individuals (1.24%). Genomic projects (n = 6,765,447) include samples (0.6%), (91.1%), (5.6%), (1.7%), (0.5%) populations (0.5%). Concerning clinical trials (n = 89,212), registries found 66.95% participants, mainly obtained Whites (25.94%), Asians (4.97%), Americans (1.08%), Hispanics (0.16%) minorities (0.9%). Thus, two tendencies observed across studies: lack information overrepresentation Caucasian/White samples/individuals. These results clearly indicate need to diversify along with novel strategies enhanced data recording reporting.